Could Clovis Oncology Inc Decline After Today’s Tip From Option Traders?

 Could Clovis Oncology Inc Decline After Today's Tip From Option Traders?

In today’s session Clovis Oncology Inc (CLVS) registered an unusually high (208) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious CLVS increase. With 208 contracts traded and 14054 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: CLVS170120C00030000 closed last at: $9.5 or 5% down. About 1.16 million shares traded hands. Clovis Oncology Inc (NASDAQ:CLVS) has risen 73.56% since March 3, 2016 and is uptrending. It has outperformed by 65.21% the S&P500.

Analysts await Clovis Oncology Inc (NASDAQ:CLVS) to report earnings on November, 3. They expect $-1.93 earnings per share, up 26.34% or $0.69 from last year’s $-2.62 per share. After $-2.07 actual earnings per share reported by Clovis Oncology Inc for the previous quarter, Wall Street now forecasts -6.76% EPS growth.

Clovis Oncology Inc (NASDAQ:CLVS) Ratings Coverage

Out of 8 analysts covering Clovis Oncology (NASDAQ:CLVS), 4 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 50% are positive. Clovis Oncology has been the topic of 23 analyst reports since September 10, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating given on Monday, November 16 by Mizuho. The firm has “Buy” rating by Stifel Nicolaus given on Wednesday, September 21. WallachBeth Capital maintained the shares of CLVS in a report on Monday, May 9 with “Hold” rating. The firm earned “Neutral” rating on Monday, January 25 by Mizuho. The firm earned “Buy” rating on Friday, August 5 by Suntrust Robinson. On Tuesday, November 17 the stock rating was downgraded by WallachBeth Capital to “Hold”. Piper Jaffray maintained the shares of CLVS in a report on Monday, November 16 with “Neutral” rating. The firm has “Neutral” rating given on Wednesday, August 24 by Mizuho. SunTrust maintained Clovis Oncology Inc (NASDAQ:CLVS) on Wednesday, August 24 with “Buy” rating. SunTrust maintained Clovis Oncology Inc (NASDAQ:CLVS) on Friday, September 23 with “Buy” rating.

According to Zacks Investment Research, “Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations. Clovis Oncology Inc. is headquartered in Colorado, USA.”

Insitutional Activity: The institutional sentiment increased to 1 in Q2 2016. Its up 0.13, from 0.87 in 2016Q1. The ratio is positive, as 36 funds sold all Clovis Oncology Inc shares owned while 26 reduced positions. 18 funds bought stakes while 44 increased positions. They now own 36.50 million shares or 0.57% less from 36.71 million shares in 2016Q1.
The New York-based Consonance Cap Mngmt Lp has invested 5.7% in Clovis Oncology Inc (NASDAQ:CLVS). Blackrock Gp Limited has invested 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Antipodean has 4.34% invested in the company for 523,000 shares. Canada Pension Plan Invest Board accumulated 0% or 32,700 shares. Parametric Port Limited holds 0% or 10,461 shares in its portfolio. Millennium Mgmt Lc holds 0.01% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS) for 297,099 shares. Nationwide Fund holds 20,623 shares or 0% of its portfolio. Sabby Mngmt Ltd Liability Co owns 59,836 shares or 0.04% of their US portfolio. Deutsche Bank & Trust Ag, a Germany-based fund reported 372,673 shares. Voya Management Ltd reported 14,489 shares or 0% of all its holdings. Rhumbline Advisers has 34,047 shares for 0% of their US portfolio. Moreover, Teacher Retirement Of Texas has 0% invested in Clovis Oncology Inc (NASDAQ:CLVS) for 4,827 shares. Great West Life Assurance Can reported 2,793 shares or 0% of all its holdings. Morgan Stanley last reported 0.01% of its portfolio in the stock. Redmile Group Incorporated Ltd Liability Com has invested 4.06% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS).

Clovis Oncology, Inc. is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The company has a market cap of $1.48 billion. The Firm is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. It currently has negative earnings. Rociletinib is an oral epidermal growth factor receptor , mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

CLVS Company Profile

Clovis Oncology, Inc., incorporated on April 20, 2009, is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Firm is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).

More recent Clovis Oncology Inc (NASDAQ:CLVS) news were published by: Fool.com which released: “Why Clovis Oncology Inc. Is Soaring Today” on September 08, 2016. Also Streetinsider.com published the news titled: “Clovis Oncology (CLVS), Lonza Enter into Manufacturing Services Agreement for …” on October 04, 2016. Businesswire.com‘s news article titled: “Clovis Oncology Announces Rucaparib Data Presentations at ESMO 2016 Congress” with publication date: September 28, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment